The Oncologist

The Oncologist Journal focuses on medical and practice issues of busy oncology, hematology and radiation professionals to aid in better cancer patient care.

[The Oncologist @OncJournal]

Submit to our special series on Clinical Cancer Epidemiology & Real-World Evidence to help advance oncology care across prevention, diagnosis, treatment, and survivorship.

👉Learn more and submit your research:
https://t.co/UqIUFGzbm2
@susanebates @gbanna74 @PasRescigno

[The Oncologist @OncJournal]

Osimertinib plus anlotinib in untreated, EGFR-mutated, advanced non-small-cell lung cancer with concurrent alterations: a multicenter phase II study
#LungCancerAwareness #lcsm
@susanebates @gbanna74 @PasRescigno
https://t.co/7LgM1mybsj

[The Oncologist @OncJournal]

Rural voices. Real data. Better cancer care. 🌿 #RuralHealth #RadOnc
@susanebates @gbanna74 @PasRescigno
https://t.co/HyXjJI4hC0

[The Oncologist @OncJournal]

Between the gate and the stars
#LungCancerAwareness #lcsm
@susanebates @gbanna74 @PasRescigno
https://t.co/WWqID0bexT

[The Oncologist @OncJournal]

This study evaluated metastatic patterns in #pancsm showing lung-only and non-liver met disease have better #OS, while liver involvement correlates with ⬇️ #OS and higher #TP53 mutations.
@susanebates @gbanna74 @PasRescigno
https://t.co/vV6lImZI3D

[The Oncologist @OncJournal]

This review examines current practice, unanswered questions, emerging strategies to optimize ICI-based therapy, and future trend. #HNSCC #Immunotherapy #ICI #KEYNOTE689 #NIVOPOSTOP
@susanebates @gbanna74 @PasRescigno
https://t.co/5qwVqrEqBg

[The Oncologist @OncJournal]

Study showed that adjuvant chemo after neoadjuvant in resected #stcsm had no #OS benefit in node negative on path but ypN+ pts w/ ⬆️ lymph node ratios & those w/ ⬇️pathologic response had ⬆️ #EFS & #OS w/ adj chemo
@susanebates @gbanna74 @PasRescigno
https://t.co/S333WhzsUb

[The Oncologist @OncJournal]

#REVERCE 📿🙏 is a PhII trial that explored sequencing of rego & anti-EGFR therapy in refractory RAS WT #crcsm. Rego first showed ⬆️ #OS but ↔️ #PFS. Premature closure & small enrollment limits optimal sequencing.
@susanebates @gbanna74 @PasRescigno
https://t.co/X1GLbACUc8

[The Oncologist @OncJournal]

🗓️ Save the Date

Go beyond the article with The Oncologist eJournal Club!

Read more about the event here: https://t.co/oyy1UwLPH2

@susanebates @gbanna74 @PasRescigno

[The Oncologist @OncJournal]

⏰ Last call! Deadline for submissions is tomorrow: October 31: https://t.co/UqIUFGzJbA

#Oncology #CallForPapers #RealWorldEvidence #CancerResearch

@susanebates @gbanna74 @PasRescigno

[The Oncologist @OncJournal]

🎉 Congratulations to the winner of the 2025 Early Career Investigator Award!

Meet the researcher behind this year's award-winning work: https://t.co/pEyjOmFQZY

#Oncology #CancerResearch

[The Oncologist @OncJournal]

Heat shock protein inhibition does not improve outcomes in endocrine-resistance ER+ metastatic breast cancer. #BreastCancerAwareness #HSP90
@susanebates @gbanna74 @PasRescigno
https://t.co/qmTdB7o5Vs

[The Oncologist @OncJournal]

Caregivers are part of the treatment experience. In 122 pts on 2nd-line therapy for metastatic breast cancer, caregiver fatigue & QoL tracked w/ pt distress over 6 mo of ePROM collection. #BreastCancerAwareness
@susanebates @gbanna74 @PasRescigno
https://t.co/weadMpysPW

[The Oncologist @OncJournal]

📣Oxford University Press invites applications for the position of Deputy Editor for The Oncologist.

Applications are due Saturday, October 31, 2026.

Find the job description and application instructions here: https://t.co/iVpbEPtmGU

@susanebates @gbanna74 @PasRescigno

[The Oncologist @OncJournal]

⏰Just one week left to submit to our special series!

Submit by October 31st: https://t.co/UqIUFGzJbA

#Oncology #CallForPapers #RealWorldEvidence #CancerResearch
@susanebates @gbanna74 @PasRescigno

[The Oncologist @OncJournal]

Highlights of ASCO 2026
@susanebates @gbanna74 @PasRescigno
https://t.co/bQAMGEnO63

[The Oncologist @OncJournal]

Distinct sleep and rest-activity profiles according to adjuvant treatment exposure in women treated for breast cancer
#BreastCancerAwareness #sleep #fatigue
@susanebates @gbanna74 @PasRescigno
https://t.co/YvhmWUhMeR

[The Oncologist @OncJournal]

Comparative safety of concurrent adjuvant trastuzumab emtansine versus trastuzumab with radiotherapy in HER2-positive early breast cancer
#BreastCancerAwareness #radiotherapy #toxicity
@susanebates @gbanna74 @PasRescigno
https://t.co/226OHuKUcC

[The Oncologist @OncJournal]

A View from the Periphery: Trial Design, Commercial Competition, and the Access Gap in Multiple Myeloma
@susanebates @gbanna74 @PasRescigno @drMehmetbaysal
https://t.co/pWsHkWcP0e

[The Oncologist @OncJournal]

There’s still time!

The Oncologist is calling for manuscripts to be included in this special series. Submission deadline: Oct 31, 2026.

📑Submit your manuscript today: https://t.co/UqIUFGzbm2
@susanebates @gbanna74 @PasRescigno

[The Oncologist @OncJournal]

This small pilot trial suggests #cannabis may improve symptoms in #pancsm w/ ≥10 mg/day #THC 🌿 linked to ⬆️symptom improvement. Higher #THC doses also correlated w/ reduced #anxiety & #insomnia. #PallOnc #SuppOnc
@susanebates @gbanna74 @PasRescigno
https://t.co/p8B7aumZjW